Skip to main content
Diagnostic Medical Systems logo

Diagnostic Medical Systems — Investor Relations & Filings

Ticker · ALDMS ISIN · FR0012202497 LEI · 969500RKTIGCNNIKIN19 PA Manufacturing
Open in API
Filings indexed 232 across all filing types
Latest filing 2021-04-21 Earnings Release
Country FR France
Listing PA ALDMS

About Diagnostic Medical Systems

https://www.dms.com/en/home/

Diagnostic Medical Systems (DMS) specializes in the development, design, and manufacturing of medical imaging systems. The company's core focus is on digital radiology and bone densitometry. Its product portfolio includes radiography and fluoroscopy systems, mobile x-ray units, surgical C-arms, and bone densitometers. DMS is engaged in developing next-generation imaging solutions aimed at improving patient care and personalized medicine. Key development projects include new mobile and surgical imaging equipment and an advanced range of bone densitometers for diagnosing and monitoring pathologies affecting bone mineral density.

Recent filings

Filing Released Lang Actions
Croissance dynamique de +18% au 1er trimestre 2021
Earnings Release Classification · 98% confidence The document is a press release dated April 21, 2021, announcing the consolidated revenue for the first quarter of 2021 ("chiffre d'affaires consolidé au titre du 1er trimestre de l'exercice 2021"). It presents key financial figures (M€) for Q1 2021 compared to Q1 2020, discusses business segment performance, and provides a financial agenda. This content aligns perfectly with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is not a comprehensive Interim Report (IR) as it only covers Q1 revenue, not a full set of interim financial statements, nor is it an Annual Report (10-K). The document is short enough to be an announcement, but its content is the result itself, not just an announcement that results are coming soon (RPA). Q1 2021
2021-04-21 French
Signature du traité d'apport liant relatif à l'apport de la division imagerie médicale de DMS Group à ASIT Biotech
M&A Activity Classification · 99% confidence The document is a press release dated April 16, 2021, detailing the signing of a contribution agreement (traité d'apport en nature) where DMS Group will contribute its medical imaging division to ASIT Biotech. This transaction involves a significant corporate restructuring, asset transfer, and a change in control, leading to ASIT Biotech becoming a listed entity focused on medical imaging. This type of announcement, detailing a major corporate transaction like a merger, acquisition, or significant asset transfer that changes the capital structure or business focus, falls under the scope of M&A Activity (TAR). It is not a standard periodic report (10-K, IR), an earnings release (ER), or a simple management/board change (MANG).
2021-04-16 French
Lettre du Président de DMS Group aux actionnaires
Legal Proceedings Report Classification · 95% confidence The document is titled "Lettre du Président de DMS Group aux actionnaires" (Letter from the Chairman of DMS Group to shareholders). It discusses the company's strategy, restructuring into distinct divisions (DMS Biotech, DMS Imaging, DMS Wellness), financing plans (SPAC-inspired fundraising), and outlook. This content is characteristic of a formal communication from management to shareholders regarding the company's overall direction and performance, often preceding or accompanying an Annual General Meeting (AGM) or serving as a high-level strategic update. Since it is a letter from the Chairman to shareholders discussing the company's structure and future, it strongly aligns with the purpose of materials shared during an Annual General Meeting (AGM-R), which covers high-level strategic updates and shareholder communication. It is not a full 10-K, a short earnings release (ER), or a formal proxy statement (DEF 14A/PSI). Given the context of a Chairman's letter to shareholders about the group's evolution, AGM-R is the most appropriate classification.
2021-04-13 French
Reprise des négociations entre ASIT biotech et DMS Group
Legal Proceedings Report Classification · 99% confidence The document text announces the resumption of discussions between two companies, DMS Group and ASIT biotech, regarding a potential transaction involving the DMS Imaging division and ASIT biotech's judicial reorganization plan. This content describes a significant corporate event related to a potential merger, acquisition, or major restructuring/partnership that impacts the corporate structure and ownership. This aligns best with the 'M&A Activity' category (TAR), which covers merger proposals or takeover bids, even if this is a restructuring/partnership leading to a potential acquisition of assets/shares. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K) as it focuses on corporate transaction news, not periodic financial results. It is too specific for a general Regulatory Filing (RNS) and clearly describes a transaction proposal, making TAR the most appropriate fit.
2021-04-08 French
Fin des discussions avec ASIT biotech
Regulatory Filings Classification · 95% confidence The document is a press release dated March 16, 2021, announcing the termination of discussions regarding a partnership with ASIT biotech. It details the reasons for the termination (failure to agree on transaction terms for the DMS Imaging division) and outlines DMS Group's future strategic plans for its medical imaging activity. This type of announcement, which communicates a significant corporate event (failure of a potential transaction/M&A activity) via a press release, is generally classified as a general regulatory announcement or a specific corporate action update. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific insider trade (DIRS), it fits best under the general regulatory announcement category, RNS, as it is a material, non-financial update released to the market. Given the context of M&A discussions ending, it is closely related to TAR (M&A Activity), but since the transaction did not proceed and this is the announcement of the *end* of discussions rather than the proposal itself, RNS serves as the appropriate general regulatory filing category for material news that doesn't fit elsewhere, although it is related to M&A activity that failed to materialize.
2021-03-16 French
Homologation du plan de réorganisation d'ASIT biotech par le Tribunal de l'entreprise de Liège
Legal Proceedings Report Classification · 99% confidence The document announces the homologation of a judicial reorganization plan for ASIT biotech by a Belgian court, which is a condition for a proposed merger/takeover by DMS Group. It references prior press releases regarding the merger announcement and states that definitive terms will be detailed later via press release. The content is focused on a significant corporate transaction (M&A activity) and related legal/regulatory steps, rather than routine financial reporting (like 10-K, ER, or IR). Since it is an announcement concerning a merger proposal/takeover bid, the most appropriate category is 'M&A Activity' (TAR). It is not a general regulatory filing (RNS) because it fits a more specific category.
2021-02-10 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.